FDA misses PDUFA review deadline for Agios' thalassemia drug
FDA misses PDUFA review deadline for Agios' thalassemia drug
Inhalt nicht verfügbar. Bitte die Originalquelle aufrufen.
FDA misses PDUFA review deadline for Agios' thalassemia drug
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.